uniQure (NASDAQ:QURE) Expected to Earn Q3 2024 Earnings of ($1.02) Per Share

uniQure (NASDAQ:QURE) – William Blair lifted their Q3 2024 earnings per share estimates for shares of uniQure in a report released on Monday, July 1st. William Blair analyst S. Corwin now forecasts that the biotechnology company will earn ($1.02) per share for the quarter, up from their previous estimate of ($1.18). The consensus estimate for uniQure’s current full-year earnings is ($4.50) per share. William Blair also issued estimates for uniQure’s Q4 2024 earnings at ($1.04) EPS, FY2024 earnings at ($4.56) EPS, Q1 2025 earnings at ($1.04) EPS, Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.99) EPS and FY2025 earnings at ($4.06) EPS.

Several other brokerages also recently weighed in on QURE. Mizuho decreased their target price on uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of uniQure in a research note on Wednesday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

uniQure Trading Down 2.5 %

QURE opened at $3.91 on Thursday. The stock has a 50-day moving average of $4.79 and a 200-day moving average of $5.38. uniQure has a 52-week low of $3.90 and a 52-week high of $11.90. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The company had revenue of $8.49 million for the quarter, compared to the consensus estimate of $2.58 million. uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%.

Institutional Trading of uniQure

A number of hedge funds have recently modified their holdings of QURE. Vestal Point Capital LP bought a new stake in shares of uniQure in the 4th quarter worth approximately $26,572,000. Citigroup Inc. raised its holdings in shares of uniQure by 667.9% in the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock worth $5,143,000 after buying an additional 666,696 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of uniQure by 173.5% in the 4th quarter. BNP Paribas Financial Markets now owns 706,670 shares of the biotechnology company’s stock worth $4,784,000 after buying an additional 448,319 shares in the last quarter. abrdn plc acquired a new position in shares of uniQure in the 4th quarter worth approximately $2,711,000. Finally, Bridger Management LLC raised its holdings in shares of uniQure by 2,917.3% in the 4th quarter. Bridger Management LLC now owns 362,349 shares of the biotechnology company’s stock worth $2,453,000 after buying an additional 350,340 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.